In this issue:
The EC Pharmaceutical Sector Inquiry
Solving the Wrong Problem The Preliminary Report on the EC Pharmaceutical Sector Inquiry: What Have We Really Learned?
If the European Commission truly wants to see why R&D is less than it would like, and generics are not competing harder with one another, it will have to broaden its focus and look at the actions of the member states in terms of price, access, and supply (all issues with no U.S. counterpar
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.138.143.72
Please verify email or join us to access premium content!